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Abstract. New insights about close connection between skeletal and immune systems have expanded vistas of modern 
medicine and tissue engineering. Intensive progress of osteoimmunology enabled the understanding of processes 
related to bone tissue from a completely new angle, both in physiological and pathological conditions. In this respect, 
macrophages stand out as cells which affect bone through the ability to secrete a range of different cytokines. 
Macrophages’ activation is directed by environmental conditions which determine the phenotype and function of these 
cells. Acquired phenotypic and functional characteristics of macrophages are changed according to changes in their 
environment. Thanks to these abilities, macrophages have great impact on bone development, bone homeostasis and 
osteoreparatory process. During bone development, macrophages can affect osteoblast differentiation and matrix 
mineralization. Coordinated action of osteoclasts and osteoblasts is important in bone tissue remodeling process. 
Also, during osteoreparation macrophages are among the first cells that will come to the site of bone injury. Their 
impact on bone is particularly visible during inflammatory phase of fracture healing. Better understanding of 
mechanisms by which macrophages exert their influence on bone would be an important step in approach to more 
specific therapies that would modulate activity of these cells and might accelerate healing of bone defects. 
Key words: macrophages, bone, bone homeostasis, osteogenesis, fracture, osteoreparation. 
Introduction 

 
The belief that bones represent inert structures has been 
disproved long ago by abundant evidence that bone 
tissue is very dynamic and that it is in constant process 
of resorption and formation [1, 2]. There are numerous data 
on direct correlation between skeletal and immune 
systems. Among various cells of immune system, 
macrophages are those that stand out by their secretory 
products which directly affect osteogenesis and 
osteoreparation [3–5]. In addition, macrophages are very 
plastic cells since they adjust their activity and change their 
phenotype according to general state of the environment. 
They are involved in several stages of osteoreparation, and 
are especially important actors during initiation of bone 
tissue healing [4]. Therefore, the possibility of modulating 
macrophages' activity would be a useful tool in an attempt 
to control osteogenesis and osteoreparation, especially 
after bone tissue injury or in pathological conditions.    
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Macrophages’ Differentiation and Activation 
Macrophages belong to a group of professional phagocytes 
which perform their functions thanks to numerous 
surface receptors and secretory products [6]. Almost all 
organs of the body contain tissue-resident macrophages, 
which play an important role in homeostatic processes [7, 
8]. Macrophages have a wide range of morphological 
characteristics that correspond to their functional state 
and environmental conditions. Different subpopulations 
of tissue-resident macrophages exist in various tissues 
[8–10]. Depending on the tissue they are placed, tissue-
resident macrophages include osteoclasts (bone), alveolar 
macrophages (lung), microglial cells (CNS), histiocytes 
(connective tissue), Kupffer cells (liver), and Langerhans 
cells (skin) [11]. 
The process of macrophages’ differentiation should 
be distinguished from activation process, which means 
that differentiated macrophages through further stimulation 
increase their capability to exert certain functions. Tissue-
resident macrophages are quiescent and characterized by 
low oxygen consumption, low expression level of major 
histocompatibility complex class II gene (MHC II), a 
little cytokine production and by preserved proliferative 
capacity. It is believed that there are two levels of 
macrophages’ activation. Initial activation (priming) leads 
to increased expression of the MHC II gene, increased 
production of cytokines and reduced proliferative capacity. 
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Priming is usually achieved by low concentrations of 
interferons (IFNs) and it is a process of preparing for a 
quick response and reaction to other cytokines, although 
macrophages are not still fully activated [12]. Macrophages 
then react to secondary signals (e.g. tumor necrosis factor-
α (TNF-α) or lipopolysaccharide (LPS)) and become fully 
activated, which means that they lose their ability to 
proliferate, but gain ability to kill parasite and tumor 
cells, and all this is accompanied by increase in oxygen 
consumption, cytokines, reactive oxygen species (ROS) 
and nitric oxide (NO) secretion [13, 14].  
Macrophages’ Classification according to 
their Functional Characteristics 
Macrophages show a remarkable plasticity through the 
ability to adapt their phenotype and function to 
environmental changes. Tissue injury, infections or tissue 
reaction to a foreign body excite quick response of these 
cells. Macrophage classification arises from their 
functional characteristics, surface markers and type of 
produced cytokines. According to their functional 
characteristics macrophages are usually classified as M1 
or M2, i.e. classically and alternatively activated 
macrophages. This nomenclature is based on the type of 
T cells (Th1 or Th2) which influence macrophages’ 
activation by distinct cytokines [15].  
M1, i.e. classically activated macrophages, are 
referred as inflammatory and can be activated by IFN-γ, 
TNF-α and LPS. They are involved in defending the host 
against various pathogens and tumors. Macrophages of 
M1 type produce ROS and NO, high level of interleukin-
12 (IL-12) and low level of IL-10 and also produce 
numerous pro-inflammatory cytokines including TNF-α, 
IL-1 and IL-6 [6].  
M2, i.e. alternatively activated macrophages, are 
referred as anti-inflammatory according to their anti-
inflammatory function, but they also regulate wound 
healing [6]. Within this type of functional macrophages 
there are three subtypes of cells with different 
physiological roles. M2a macrophages are involved in 
later events of tissue repair, and they are activated by 
cytokines IL-4 and IL-13. M2c macrophage subtype is 
induced by IL-10 or glucocorticoids, and this subtype 
has anti-inflammatory function. M2b macrophages also 
achieve anti-inflammatory activity via IL-10, but also 
synthesize pro-inflammatory cytokines (IL-1 and TNF-
α), like M1 type macrophages [16]. 
The relationship between Skeletal and 
Immune Systems from Macrophages’ 
Perspective 
At the beginning of the new millennium osteoimmunology 
was defined as new branch of science that deals with 
interactions between cells of immune system and bone 
tissue cells [17]. Immune cells produce cytokines which 
can have a part in normal bone tissue healing [4], but 
also can affect appearance and flow of different 
pathological conditions [18].  
The connection between bone and immune system 
exists on at least three levels. Firstly, bone marrow is 
anatomically located in bones, so the mutual interaction 
of immune and bone cells is unavoidable. Secondly, 
cells of immune system originate from hematopoietic stem 
cells of bone marrow, similar to osteoclasts which 
structurally and functionally belong to bone tissue. Thirdly, 
the two systems share various cytokines, growth factors, 
signaling molecules and transcription factors [19]. 
Connection and conditionality between cells of bone 
and immune system is clearly represented trough 
osteoclastogenesis, since many factors that affect precursors 
of osteoclasts can be synthesized by inflammatory cells too. 
Furthermore, osteoclasts and immune cells share the same 
progenitors through differentiation process [20]. Osteoclasts 
originate from bone marrow pluripotent hematopoietic stem 
cell and are by themselves specialized bone tissue 
macrophages [11, 21]. Likewise, individual macrophages 
can fuse together to form osteoclasts [22]. The two most 
important cytokines that are necessary for unobstructed 
osteoclastogenesis are receptor activator of nuclear factor-
κB ligand (RANKL) and macrophage colony-stimulating 
factor (M-CSF), which can be secreted among others by 
inflammatory cells. RANKL is a cytokine expressed by 
osteoblasts, stromal cells, and activated T lymphocytes 
[23] and belongs to TNF superfamily. RANKL binds to 
RANK-receptor which exists on the surfaces of osteoclast 
precursors. Osteoprotegerin (OPG), secretory product of 
osteoblasts and numerous hematopoietic cells, is RANKL-
competitor and has anti-osteoclastogenic function [24]. M-
CSF is produced by bone marrow stromal cells, 
osteoblasts and T lymphocytes and it is responsible for 
proliferation and survival of osteoclast progenitors, as 
well as mature osteoclasts [25]. The fact that these two 
factors can be synthesized by cells of immune system 
indicates that in this way immune system can affect bone 
tissue. This correlation is particularly visible in some 
bone diseases [26]. 
Macrophages/monocytes can regulate bone 
development and homeostasis through secretion of 
numerous cytokines and other molecules, although their 
role in abovementioned processes is still not fully 
understood. Many of these secretory products are pro-
angiogenic and pro-osteogenic [27]. It has been 
experimentally proved that macrophages are involved in 
osteoblast differentiation [3] and mineralization process 
[3, 28].  In addition, macrophages may activate other 
cells from their environment to secrete certain cytokines 
important for the osteogenic process [27]. Chang and 
coworkers point to macrophage population termed 
OsteoMacs in murine and human osteal tissue, significant 
in bone homeostasis. OsteoMacs are defined as stellate-
shaped resident bone tissue macrophages located on 
endosteal and periosteal surfaces. Difference between 
OsteoMacs and osteoclasts is, among others, based on 
F4/80
+
TRAP
-
 phenotype of OsteoMacs and F4/80
-
TRAP
+
 phenotype of osteoclasts. Also, OsteoMacs in 
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physiological conditions are not osteoclast precursors, 
while they may be in pathological conditions. These 
cells interact with osteoblasts, regulate their function 
and mineralization process through induction of gene 
for osteocalcin in vitro.  [29]. OsteoMacs at bone modeling 
and remodeling sites form canopy structures over mature 
osteoblasts. Depletion of these cells leads to disappearance 
of mature osteoblasts from bone modeling surfaces. During 
bone remodeling OsteoMacs, like osteoclasts, provide 
coupling signals, most probably transforming growth 
factor beta (TGF-β) and ephrin B2 to osteoblasts, affecting 
bone formation [30]. 
Another unique ability of macrophages is to quickly 
respond to chemoattractants from the site of tissue injury. 
During fracture healing, macrophages come to the site of 
injury and release various cytokines that promote 
angiogenesis and recruitment of mesenchymal stem cells 
[27]. Presence of blood vessels and mesenchymal stem 
cells at defect site is crucial for proper osteoreparatory 
process [31, 32]. All of these macrophages’ capabilities are 
in favor of their potential use in bone tissue engineering. 
Inflammatory process plays an important role in 
initiating bone regeneration after injury. On the other 
hand, some inflammatory diseases or reactions to 
implanted material can lead to chronic inflammation, 
which has a destructive effect on bone tissue [33]. One 
such example of bone destruction associated with 
inflammation is reumatoid arthritis [34]. Therefore, 
studies concerning control of inflammatory signal are of 
the great significance. 
The role of macrophages in the process of fracture 
healing is discussed in the following sections. 
Repair of Bone Defects 
Bone healing process usually goes through three 
dynamic phases that overlap each other and are named 
inflammatory, reparative and remodeling phase. Therefore, 
repair of bone defects (fractures) is characterized by an 
initial inflammatory reaction accompanied by cell 
proliferation and remodeling, which ultimately leads to 
bone reconstruction. The main actors of inflammatory 
process are macrophages, which migrate to the site of 
injury [4]. These cells also release factors involved in the 
formation and resorption of bone tissue. 
Inflammatory phase 
Together with bone damage, as consequence of fracture, 
damage of surrounding tissues and blood vessels also 
develops. Blood coagulation results in formation of 
hematoma. Due to blood vessels injury in the zone of 
bone fracture, lack of oxygen and nutrients occurs, 
leading to premature cell apoptosis and to the formation 
of necrotic tissue. Necrotic tissue, platelet-derived growth 
factor (PDGF) from blood clot and growth factors from 
extracellular matrix (TGF-β for example) act as 
chemoattractants for inflammatory cells (macrophages, 
monocytes, lymphocytes and neutrophils) and fibroblasts, 
and provoke acute inflammatory response. This initial 
phase of bone tissue healing reaches its maximum 24-48 
h after injury and completes in about 1 to 2 weeks [35, 
36]. Actually, it is believed that these first 2 weeks are 
the milestone in bone healing process [37]. 
Inflammatory phase is characterized by dynamic 
processes such as formation of granulomatous tissue, 
ingrowth of blood vessels and migration of mesenchymal 
stem cells to the fracture site [38, 39]. Likewise, levels of 
several pro-inflammatory cytokines, including TNF-α, 
IL-1, IL-6, IL-11 and IL-18 are significantly increased 
[36, 38]. Although it is known that extended or chronic 
expression of pro-inflammatory cytokines might have 
negative effect on bone, short-term and highly specific 
secretion of these molecules is extremely important for 
tissue regeneration [40, 41]. These signals recruit 
inflammatory cells and promote angiogenesis [38]. It is 
believed that TNF-α as a product of inflammatory cells, 
especially macrophages, mediates the induction of 
secondary pro-inflammatory signals, which are 
chemoattractants for different cells and also can induce 
osteogenic differentiation of osteoblast-like cells [42, 43, 
44]. Along with them, TGF-β1 and PDGF from blood clot 
also serve as guides to differentiation and proliferation of 
mesenchymal stem cells [45]. Over time, the acute 
inflammatory response is being replaced by the next phase. 
Reparative phase 
Reparatory phase starts with reorganization of hematoma. 
Numerous cells which came to the fracture site during 
inflammatory phase produce callus. Callus consists of 
cartilage and immature bone tissue and has function to 
increase stability of the fracture. Formed cartilage through 
ossification process becomes bone, under the influence of 
TGF-β2, TGF-β3, bone morphogenetic proteins (BMPs) 
and other signaling molecules [35, 38, 42, 46]. During 
reparative phase inflammatory cells and pro-inflammatory 
cytokines are absent [39]. 
Remodeling phase 
During remodeling phase through the activity of 
osteoblasts and osteoclasts initial immature woven bone 
is replaced by mature lamellar bone. This phase, which 
begins 8 to 12 weeks after injury, is strongly osteoclast-
dependent and it is regulated by a number of pro-
inflammatory signals like IL-1, IL-6, IL-11, IL-12 and 
TNF-α [36, 38, 39]. Remodeling phase is the longest 
phase during bone healing process and can last up to 
several years.  
The role of Macrophages during Fracture 
Healing Process 
Macrophages play a significant role in bone healing 
process, in initial as well as the final stage. Immediately 
after fracture, macrophages along with neutrophils and 
lymphocytes penetrate into hematoma. Monocytes/ 
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macrophages produce BMP-2, one of the key factors 
involved in the early osteogenic process. In fact, BMP-2 
directs stem cells toward osteoblast differentiation in 
vitro, as well as in vivo. Pirraco and coworkers used 
experiments with co-cultures of human peripheral blood 
monocytes/macrophages and human bone marrow 
stromal cells (hBMSCs) which have shown that 
hBMSCs from co-cultures have higher proliferative 
capacity and higher alkaline phosphatase activity in 
regard to hBMSCs monocultures [47]. Schlundt and 
colleagues have worked with murine experimental 
model which included macrophage reduction using 
clodronate liposomes during bone healing process. In 
their experiments macrophages’ reduction had no effect 
on early stages of fracture healing, while they had 
altered endochondral ossification through delayed hard 
callus formation [48]. 
Bone tissue is well vascularized so angiogenesis and 
vascularization are essential for unobstructed repair of 
bone tissue after injury [31, 49, 50]. According to 
literature data it is known that macrophages are able to 
affect all stages of angiogenesis thanks to their secretory 
products [51]. Stimulated macrophages release pro-
angiogenic cytokines and growth factors, as well as 
enzymes that degrade extracellular matrix and enable 
releasing of “trapped” growth factors (bFGF, TGF-beta, 
GM-CSF) which also have proangiogenic activity [52]. 
Inclusion of macrophages (induced from THP-1 
monocytic cell line treated with PMA (phorbol-12-
myristate-13- acetate)) in co-culture made of human 
outgrowth endothelial cells (OECs) and primary 
osteoblasts leads to multiplying of microvessel-like 
structures formed by OECs and higher production of 
vascular endothelial growth factor (VEGF) compared to 
co-culture. Likewise, in triple-culture expression of IL-
6, IL-8 and TNF-α was upregulated, indicating 
beneficial effects of pro-inflammatory cytokines in 
osteoreparation [53]. 
M1 type macrophages are the first that could be 
found at the site of tissue injury, with role to engulf 
necrotic material and to synthesize pro-inflammatory 
cytokines, ROS and NO. Guihard and coworkers found 
that M1 type macrophages stimulate osteogenic process 
through production of Oncostatin M (OSM), member of 
IL-6 cytokine family, which induce osteoblast 
differentiation and mineralization. [3]. Other experiments 
based on juxtacrine interaction in co-cultures composed 
of primary mouse macrophages and bone marrow stromal 
cells (BMSCs) resulted in enhanced proliferation and 
migration of stem cells which was mediated with 
increased macrophage IL-6 production in these co-
cultures [54]. 
M1 macrophages are later replaced by M2 type that 
produces IL-10, TGF-β, as well as other anti-inflammatory 
cytokines, which are essential for proper wound healing. 
Actually, due to their plasticity macrophages can switch 
from M1 to M2 phenotype [55, 56]. It has been 
experimentally proved in mouse osteotomy model that 
induction of M2 macrophages during fracture healing 
process enhances bone formation [48]. Loi and colleagues 
had investigated the effect of M1 and M2 type 
macrophages on osteogenesis in vitro in co-cultures of 
polarized primary murine macrophages and preosteoblastic 
MC3T3-E1 cells [57]. In each co-culture type osteogenic 
differentiation of MC3T3-E1 cells was increased and 
switching of macrophage phenotype from M1 to M2 
through IL-4 application had enhanced osteogenic ability 
of MC3T3-E1 cells in co-cultures. It has been confirmed 
by these experiments that inflammatory phase is necessary 
before healing process is initiated. 
Above all, action of these two types of macrophages 
had to be balanced. If M1 type macrophage activity 
overcomes macrophages of M2 type, that can lead to 
further tissue damaging, while the opposite case can 
lead to fibrosis [58]. 
During inflammatory phase macrophages remove 
necrotic tissue and secrete a number of pro-inflammatory 
cytokines such as TNF-α and IL-1. The aforementioned 
pro-inflammatory cytokines reach maximal concentration 
24 h after tissue injury [59]. At fracture site TNF-α can 
have a dual function that depends on which of the two cell 
receptor (TNFR1 and TNFR2) TNF-α binds [36]. IL-1 can 
exists in two forms: IL-1α and IL-1β. While IL-1α 
upregulates inflammation [60], IL-1β is thought to have a 
positive effect on mesenchymal stem cells differentiation 
into osteoblasts [61] and proliferation of osteoblast-like 
cells [43]. 
During remodeling phase TNF-α concentration rises 
again [59]. This cytokine binds to TNFR1 which exists 
on preosteoclasts’ surfaces [62] and in this way has 
impact on osteoclastogenesis [36]. At the same time, 
along with TNF-α, concentration of IL-1 increases and 
affects degradation of cartilage matrix during its 
maturation into bone matrix [36]. 
Macrophages as in vitro Model 
in Bone Tissue Engineering  
In some cases, when large bone defects occurred, bone 
tissue is not able to compensate the loss so it is 
necessary to use different bone substitutes. Bone 
substitutes most often include biomaterials based on 
tricalcium phosphates, hydroxyapatites, collagen and 
composites made from both inorganic and organic 
compounds. Also, 3D scaffolds are very useful because 
of their characteristic 3D structure that mimics the 
structure of living tissue. All of these materials can 
produce inflammatory reactions of macrophages in vivo 
when implanted into the defect area. Intensity of 
inflammation can greatly affect the course of the 
healing. Bearing in mind that injury itself creates local 
inflammatory reaction, if materials further stimulate this 
process, that could lead to the creation of fibrous tissue 
and inadequate healing process. Biomaterials that are 
nowadays increasingly used in bone tissue engineering 
are designed to have a stimulating effect on osteogenic 
process without having potential to induce or prolong 
inflammatory response of macrophages at injury site. 
Therefore, it is very important to show that biomaterials 
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are immunocompatible. For assessing the response of 
macrophages to different biomaterials, which can be 
potentially applied in bone tissue engineering and 
regenerative medicine, in vitro models of macrophages 
are used very often. The examination can be carried out 
on peritoneal macrophages, peripheral blood monocytes 
and different cell lines. Most commonly used cell line 
for these purposes is RAW 264.7 cell line. As previously 
stated in this paper, for the normal flow of healing 
process it is essential that there is a balance between M1 
and M2 macrophages. It is therefore important to examine 
how biomaterial of interest affects the polarization of 
macrophages [63–65]. Another very important 
characteristic that biomaterials should have is to induce 
controlled and moderate phagocytosis by macrophages. 
Different in vitro approaches of materials testing on 
macrophages are used, such as direct or indirect contact 
assays with both direct application of materials' particles 
or application of materials' extracts. In both assays 
phagocytosis can be measured quantitatively by using 
standard phagocytosis tests such as NBT test [5] or 
Neutral red uptake test, or analyzed through materials' 
particles uptake assay by transmission electron 
microscope (TEM) [65, 66]. For assessing the production 
of pro-inflammatory and anti-inflammatory cytokine 
release from macrophages stimulated with biomaterial 
particles or extracts, the most frequently performed 
method is determination of cytokine level by ELISA 
assay [67–70]. For this purpose, biological assay such as 
L929 assay can also be used [5]. Macrophages can also 
be used to simulate an inflammatory state in vitro in 
order to examine how different factors released from 
activated macrophages can influence the osteogenic 
differentiation of cells [71].  
Conclusion 
Science progress and better understanding of pleiotropic 
role of macrophages in a variety of biological and 
pathological processes put them at the top of “cell 
pyramid” because of their great influence on all aspects 
of tissue homeostasis and tissue reparation. It is 
believed that these phagocytes, as well as molecules 
they are secreting (especially during inflammatory 
phase), are the key factors for the successful bone tissue 
repair. Future research should be directed toward 
modulation of macrophage’s activity which might have 
positive influence on the final result of osteogenesis and 
osteoreparatory process. 
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